Liquidia Technologies, Inc. Aktie News

Liquidia Corporation (LQDA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

The biotech posted preliminary sales results for Yutrepia. This is its latest commercialized product, approved by the FDA in May 2025.

Liquidia Corporation remains a Buy for risk-tolerant biotech investors, supported by strong Yutrepia launch metrics and product differentiation in PAH and PH-ILD. LQDA's Yutrepia demonstrates superior tolerability, higher achievable dosing, and rapid titration versus Tyvaso, driving robust commercial uptake and market share gains. Key binary risk centers on the imminent IP litigation outcome ve...

Liquidia Corporation ( LQDA ) Jefferies London Healthcare Conference 2025 November 18, 2025 8:00 AM EST Company Participants Roger Jeffs - CEO & Director Michael Kaseta - COO & CFO Conference Call Participants Amy Li - Jefferies LLC, Research Division Presentation Amy Li Jefferies LLC, Research Division Hi, everyone, thanks so much for attending the Liquidia fireside chat. Day 2 of the conferen...

California-based TCG Crossover Management added 1.7 million shares of Liquidia for an estimated $38.9 million in the third quarter. The position represented 1.9% of reported assets at quarter-end.

Liquidia Corporation has just posted strong Q3 results after a recent FDA approval, and the commercial launch of YUTREPIA is showing solid early sales traction. The Q3 earnings beat has triggered numerous upward price target revisions for LQDA stock from analyst firms. Liquidia has a solid balance sheet and is well on its way to consistent profitability.

Liquidia Corporation ( LQDA ) Q3 2025 Earnings Call November 3, 2025 8:30 AM EST Company Participants Jason Adair - Chief Business Officer Roger Jeffs - CEO & Director Michael Kaseta - COO & CFO Scott Moomaw - Chief Commercial Officer Rajeev Saggar - Chief Medical Officer Russell Schundler - General Counsel & Corporate Secretary Conference Call Participants Amy Li - Jefferies LLC, Research Divi...

MORRISVILLE, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company revolutionizing care for patients with challenging respiratory and vascular diseases, announced today that members of the company's executive leadership team will be providing updates on the company's business during fireside chats at the following two investor conferences in No...